

Jacques P Brown

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8096022/jacques-p-brown-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

17,550
citations

65
h-index

129
g-index

225
ext. papers

19,987
ext. citations

6.3
avg, IF

6.03
L-index

#	Paper	IF	Citations
218	Attenuated clinical and osteoclastic phenotypes of Paget's disease of bone linked to the p.Pro392Leu/SQSTM1 mutation by a rare variant in the DOCK6 gene.. <i>BMC Medical Genomics</i> , 2022 , 15, 41	3.7	0
217	Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.. <i>Archives of Osteoporosis</i> , 2022 , 17, 71	2.9	0
216	Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results From the FRAME Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2021 ,	6.3	2
215	Long-Term Treatment of Postmenopausal Osteoporosis. <i>Endocrinology and Metabolism</i> , 2021 , 36, 544-552	5.5	1
214	Skeletal responses to romosozumab after 12 months of denosumab. <i>JBMR Plus</i> , 2021 , 5, e10512	3.9	7
213	Vertebral Fractures: Which Radiological Criteria Are Better Associated With the Clinical Course of Osteoporosis?. <i>Canadian Association of Radiologists Journal</i> , 2021 , 72, 150-158	3.9	5
212	A scorecard for osteoporosis in Canada and seven Canadian provinces. <i>Osteoporosis International</i> , 2021 , 32, 123-132	5.3	3
211	Simulated effects of early menopausal bone mineral density preservation on long-term fracture risk: a feasibility study. <i>Osteoporosis International</i> , 2021 , 32, 1313-1320	5.3	2
210	Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. <i>BMC Musculoskeletal Disorders</i> , 2021 , 22, 105	2.8	10
209	Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada. <i>Osteoporosis International</i> , 2021 , 32, 1753-1761	5.3	4
208	Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada. <i>BMC Musculoskeletal Disorders</i> , 2021 , 22, 224	2.8	4
207	Duration-Dependent Increase of Human Bone Matrix Mineralization in Long-Term Bisphosphonate Users with Atypical Femur Fracture. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1031-1041	6.3	3
206	Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. <i>Osteoporosis International</i> , 2021 , 1	5.3	1
205	Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 2139-2152	6.3	5
204	Clinical phenotype of adult offspring carriers of the p.Pro392Leu mutation within the gene in Paget's disease of bone. <i>Bone Reports</i> , 2020 , 13, 100717	2.6	0
203	A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. <i>Osteoporosis International</i> , 2020 , 31, 2231-2241	5.3	10
202	Change in Quantitative Ultrasound-assessed Speed of Sound as a Function of Age in Women and Men and Association With the Use of Antiresorptive Agents: The Canadian Multicentre Osteoporosis Study. <i>Journal of Clinical Densitometry</i> , 2020 , 23, 549-560	3.5	0

201	Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. <i>Osteoporosis International</i> , 2020 , 31, 181-191	5.3	16
200	Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1597-1608	6.3	54
199	Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. <i>Osteoporosis International</i> , 2019 , 30, 1855-1864	5.3	9
198	Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos). <i>Archives of Osteoporosis</i> , 2019 , 14, 49	2.9	15
197	Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1033-1040	6.3	48
196	Performance of predictive tools to identify individuals at risk of non-traumatic fracture: a systematic review, meta-analysis, and meta-regression. <i>Osteoporosis International</i> , 2019 , 30, 721-740	5.3	27
195	Gene-environment interactions in Paget's disease of bone. <i>Joint Bone Spine</i> , 2019 , 86, 373-380	2.9	4
194	The Radiology of Osteoporotic Vertebral Fractures Revisited. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 409-418	6.3	41
193	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1397-1406	6.3	99
192	Comparative Analysis of the Radiology of Osteoporotic Vertebral Fractures in Women and Men: Cross-Sectional and Longitudinal Observations from the Canadian Multicentre Osteoporosis Study (CaMos). <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 569-579	6.3	57
191	Effect of genetic variants of OPTN in the pathophysiology of Paget's disease of bone. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 143-151	6.9	9
190	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 298-306	6.3	48
189	Ly6C monocytes facilitate transport of Murid herpesvirus 68 into inflamed joints of arthritic mice. <i>European Journal of Immunology</i> , 2018 , 48, 250-257	6.1	4
188	Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2498-2509	5.6	51
187	Molecular effect of an OPTN common variant associated to Paget's disease of bone. <i>PLoS ONE</i> , 2018 , 13, e0197543	3.7	4
186	Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. <i>Archives of Osteoporosis</i> , 2018 , 13, 85	2.9	12
185	Facteurs environnementaux associ�s aux formes familiales et non familiales de maladie osseuse de Paget. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018 , 85, 375-380	0.1	
184	Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 190-198	6.3	306

183	Number, Location, and Time Since Prior Fracture as Predictors of Future Fracture in the Elderly From the General Population. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1956-1966	6.3	13
182	Environmental factors associated with familial or non-familial forms of Paget's disease of bone. <i>Joint Bone Spine</i> , 2017 , 84, 719-723	2.9	9
181	Safety Observations With 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1481-1485	6.3	17
180	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 513-523	18.1	419
179	Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1956-1962	6.3	58
178	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. <i>Journal of Clinical Densitometry</i> , 2017 , 20, 8-24	3.5	125
177	Antiresorptives: Safety Concerns-Clinical Perspective. <i>Toxicologic Pathology</i> , 2017 , 45, 859-863	2.1	7
176	Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget's disease of bone. <i>BMC Medical Genetics</i> , 2017 , 18, 133	2.1	9
175	Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 1585-1594	40	205
174	Atypical femur fractures: a survey of current practices in orthopedic surgery. <i>Osteoporosis International</i> , 2017 , 28, 3271-3276	5.3	3
173	Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 181-187	6.3	78
172	Sex-specific association between obesity and self-reported falls and injuries among community-dwelling Canadians aged 65 years and older. <i>Osteoporosis International</i> , 2017 , 28, 483-494	5.3	24
171	Comparison of Speed of Sound Measures Assessed by Multisite Quantitative Ultrasound to Bone Mineral Density Measures Assessed by Dual-Energy X-Ray Absorptiometry in a Large Canadian Cohort: the Canadian Multicentre Osteoporosis Study (CaMos). <i>Journal of Clinical Densitometry</i> , 2016 , 19, 234-41	3.5	12
170	Retraction Notice to "Kidney Function and Rate of Bone Loss at the Hip and Spine: The Canadian Multicentre Osteoporosis Study" [Am J Kidney Dis. 55(2):291-299]. <i>American Journal of Kidney Diseases</i> , 2016 , 68, 333	7.4	
169	Incidence and Characteristics of Atypical Femoral Fractures: Clinical and Geometrical Data. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 767-76	6.3	48
168	Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 3163-70	5.6	126
167	The current economic burden of illness of osteoporosis in Canada. <i>Osteoporosis International</i> , 2016 , 27, 3023-32	5.3	75
166	Loss of health related quality of life following low-trauma fractures in the elderly. <i>BMC Geriatrics</i> , 2016 , 16, 84	4.1	39

165	Overexpression of TLR2 and TLR9 on monocyte subsets of active rheumatoid arthritis patients contributes to enhance responsiveness to TLR agonists. <i>Arthritis Research and Therapy</i> , 2016 , 18, 10	5.7	48
164	Assessment of femur geometrical parameters using EOS imaging technology in patients with atypical femur fractures; preliminary results. <i>Bone</i> , 2016 , 83, 184-189	4.7	26
163	Development of a molecular test of Paget's disease of bone. <i>Bone</i> , 2016 , 84, 213-221	4.7	5
162	Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics. <i>Bone</i> , 2016 , 86, 139-42	4.7	13
161	Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1353-63	5.6	42
160	Dietary patterns in men and women are simultaneously determinants of altered glucose metabolism and bone metabolism. <i>Nutrition Research</i> , 2016 , 36, 328-336	4	16
159	Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease. <i>Journal of Clinical Investigation</i> , 2016 , 126, 1012-22	15.9	24
158	Paget's Disease of Bone 2016 , 105-118		2
157	Bone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practice. <i>International Journal of Women's Health</i> , 2016 , 8, 537-547	2.8	10
156	ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. <i>American Journal of Human Genetics</i> , 2016 , 98, 275-86	11	39
155	Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics". <i>Bone</i> , 2016 , 89, 75-76	4.7	1
154	Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. <i>Osteoporosis International</i> , 2016 , 27, 2835-2844	5.3	40
153	NR4A1-dependent Ly6C monocytes contribute to reducing joint inflammation in arthritic mice through Treg cells. <i>European Journal of Immunology</i> , 2016 , 46, 2789-2800	6.1	20
152	A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1429-39	6.3	40
151	Detection of SQSTM1/P392L post-zygotic mutations in Paget's disease of bone. <i>Human Genetics</i> , 2015 , 134, 53-65	6.3	12
150	Ten-year incident osteoporosis-related fractures in the population-based Canadian Multicentre Osteoporosis Study - comparing site and age-specific risks in women and men. <i>Bone</i> , 2015 , 71, 237-43	4.7	48
149	Assessment of the educational impact of an information leaflet on the knowledge of complications in systemic sclerosis. <i>Joint Bone Spine</i> , 2015 , 82, 373-5	2.9	2
148	Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. <i>Clinical Endocrinology</i> , 2015 , 82, 359-68	3.4	31

147	Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 46-54	6.3	59
146	Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 3-23	6.3	680
145	Response to: Comment on: "Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis". <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1939-40	6.3	3
144	A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. <i>Menopause</i> , 2015 , 22, 806-13	2.5	62
143	Paget's disease of bone: an osteoimmunological disorder?. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 4695-707	4.4	14
142	Impact of air pollutants on oxidative stress in common autophagy-mediated aging diseases. <i>International Journal of Environmental Research and Public Health</i> , 2015 , 12, 2289-305	4.6	19
141	Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. <i>Osteoporosis International</i> , 2015 , 26, 361-72	5.3	44
140	Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, E487-92	5.6	13
139	Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2051-6	6.3	47
138	The impact of educational interventions on modifiable risk factors for osteoporosis after a fragility fracture. <i>Osteoporosis International</i> , 2014 , 25, 1821-30	5.3	8
137	Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3070-9	5.6	5
136	Alternative splicing in osteoclasts and Paget's disease of bone. <i>BMC Medical Genetics</i> , 2014 , 15, 98	2.1	13
135	Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. <i>Osteoporosis International</i> , 2014 , 25, 1953-61	5.3	37
134	Identification of rare genetic variants in novel loci associated with Paget's disease of bone. <i>Human Genetics</i> , 2014 , 133, 755-68	6.3	15
133	Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. <i>Bone</i> , 2014 , 58, 48-54	4.7	118
132	Romosozumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , 2014 , 370, 412-20	59.2	781
131	SAT0525 Environmental Factors Associated with Paget's Disease of Bone or with the Sqstm1/P392I Mutation Carriage. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 781.2-781	2.4	2
130	Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 158-65	6.3	85

129	Heterogeneity in skeletal load adaptation points to a role for modeling in the pathogenesis of osteoporotic fracture. <i>Journal of Clinical Densitometry</i> , 2014 , 17, 170-6	3.5	5
128	Normative data for multisite quantitative ultrasound: the Canadian Multicenter Osteoporosis Study. <i>Journal of Clinical Densitometry</i> , 2014 , 17, 534-40	3.5	5
127	Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. <i>Canadian Family Physician</i> , 2014 , 60, 324-33	0.9	82
126	Genetic association study of Dickkopf-1 and sclerostin genes with paget disease of bone. <i>Calcified Tissue International</i> , 2013 , 93, 405-12	3.9	8
125	High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. <i>Current Osteoporosis Reports</i> , 2013 , 11, 136-46	5.4	148
124	The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 4483-92	5.6	202
123	Canadian Association of Radiologists Technical Standards for Bone Mineral Densitometry Reporting. <i>Canadian Association of Radiologists Journal</i> , 2013 , 64, 281-94	3.9	13
122	Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 250-6	3.5	24
121	A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. <i>Allergy, Asthma and Clinical Immunology</i> , 2013 , 9, 30	3.2	493
120	Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 746-52	6.3	100
119	Multisite quantitative ultrasound for the prediction of fractures over 5 years of follow-up: the Canadian Multicentre Osteoporosis Study. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2027-34	6.3	31
118	Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013 , 5, 291-304	3.8	34
117	Direct medical resource utilization associated with osteoporosis-related nonvertebral fractures in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 360-71	6.3	11
116	Evidence for impaired skeletal load adaptation among Canadian women with type 2 diabetes mellitus: insight into the BMD and bone fragility paradox. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 1401-5	12.7	19
115	Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget's disease. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1489-500	6.3	12
114	Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 3010-8	5.6	40
113	Fracture risk prediction: importance of age, BMD and spine fracture status. <i>BoneKEy Reports</i> , 2013 , 2, 404		24
112	Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study. <i>BoneKEy Reports</i> , 2013 , 2, 442		10

111	A critical review of brand and generic alendronate for the treatment of osteoporosis. <i>SpringerPlus</i> , 2013 , 2, 550		8
110	Trends in hip fracture rates in Canada: an age-period-cohort analysis. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1283-9	6.3	31
109	Epidemiogenetic study of French families with Paget's disease of bone. <i>Joint Bone Spine</i> , 2012 , 79, 393-82.9		27
108	Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 694-701	6.3	235
107	Algorithms can be used to identify fragility fracture cases in physician-claims databases. <i>Osteoporosis International</i> , 2012 , 23, 483-501	5.3	47
106	Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?. <i>Osteoporosis International</i> , 2012 , 23, 327-37	5.3	97
105	Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. <i>Osteoporosis International</i> , 2012 , 23, 267-76	5.3	36
104	The burden of illness of osteoporosis in Canada. <i>Osteoporosis International</i> , 2012 , 23, 2591-600	5.3	79
103	Étude épidémiologique de familles françaises avec maladie osseuse de Paget. <i>Revue Du Rhumatisme (Edition Française)</i> , 2012 , 79, 234-240	0.1	
102	Genetic association study of UCMA/GRP and OPTN genes (PDB6 locus) with Paget's disease of bone. <i>Bone</i> , 2012 , 51, 720-8	4.7	16
101	The burden of illness of osteoporosis in Canadian men. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1830-8	6.3	28
100	Direct medical costs attributable to peripheral fractures in Canadian post-menopausal women. <i>Osteoporosis International</i> , 2012 , 23, 1757-68	5.3	26
99	Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2799-808	5.6	73
98	Canadian Association of Radiologists technical standards for bone mineral densitometry reporting. <i>Canadian Association of Radiologists Journal</i> , 2011 , 62, 166-175	3.9	9
97	Osteoporosis Canada 2010 guidelines for the assessment of fracture risk. <i>Canadian Association of Radiologists Journal</i> , 2011 , 62, 243-50	3.9	51
96	A community-based clinical trial of Intra-Venous zoledronic acid once Yearly in comparison to oral bisphosphonates in postmenopausal women with osteoporosis: the IVORY trial Methodological considerations. <i>Contemporary Clinical Trials</i> , 2011 , 32, 741-6	2.3	1
95	Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. <i>Cell Metabolism</i> , 2011 , 13, 23-34	24.6	90
94	Novel SQSTM1 mutations in patients with Paget's disease of bone in an unrelated multiethnic American population. <i>Bone</i> , 2011 , 48, 456-60	4.7	29

93	Emerging strategies and therapies for treatment of Paget's disease of bone. <i>Drug Design, Development and Therapy</i> , 2011 , 5, 225-39	4.4	12
92	A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. <i>Pain Practice</i> , 2011 , 11, 33-41	3	158
91	Genetics of bone diseases: Paget's disease, fibrous dysplasia, osteopetrosis, and osteogenesis imperfecta. <i>Joint Bone Spine</i> , 2011 , 78, 252-8	2.9	31
90	Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. <i>Osteoporosis International</i> , 2011 , 22, 567-76	5.3	103
89	Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. <i>Osteoporosis International</i> , 2011 , 22, 789-96	5.3	36
88	Fracture prediction and calibration of a Canadian FRAX [®] tool: a population-based report from CaMos. <i>Osteoporosis International</i> , 2011 , 22, 829-37	5.3	129
87	The impact of two educational interventions on osteoporosis diagnosis and treatment after fragility fracture: a population-based randomized controlled trial. <i>Osteoporosis International</i> , 2011 , 22, 2963-72	5.3	30
86	A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2261-70	6.3	91
85	Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2737-44	6.3	50
84	Administration of annual oral high-dose vitamin D to community-dwelling older women in autumn and winter months increases risk of falls and fractures. <i>Evidence-Based Medicine</i> , 2010 , 15, 175-6		
83	Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1 year compared with historical placebo. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 56-62	3.5	4
82	Normative bone mineral density z-scores for Canadians aged 16 to 24 years: the Canadian Multicenter Osteoporosis Study. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 267-76	3.5	11
81	2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. <i>Cmaj</i> , 2010 , 182, 1864-73	3.5	768
80	Gene expression profile in osteoclasts from patients with Paget's disease of bone. <i>Bone</i> , 2010 , 46, 598-603	4.7	17
79	Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. <i>Bone</i> , 2010 , 47, 131-9	4.7	68
78	Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 72-81	6.3	318
77	Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 291-9	7.4	45
76	Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. <i>BMC Musculoskeletal Disorders</i> , 2010 , 11, 130	2.8	62

75	Low urine pH and acid excretion do not predict bone fractures or the loss of bone mineral density: a prospective cohort study. <i>BMC Musculoskeletal Disorders</i> , 2010 , 11, 88	2.8	25
74	Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2256-65	6.3	173
73	Étiologie des maladies osseuses. <i>Revue Du Rhumatisme Monographies</i> , 2010 , 77, 314-320	0	
72	The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. <i>Molecular Endocrinology</i> , 2009 , 23, 1668-80		62
71	Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. <i>Clinical Therapeutics</i> , 2009 , 31, 272-85	3.5	18
70	Risk factors for low BMD in healthy men age 50 years or older: a systematic review. <i>Osteoporosis International</i> , 2009 , 20, 507-18	5.3	97
69	The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. <i>Osteoporosis International</i> , 2009 , 20, 703-14	5.3	123
68	Factors influencing the treatment of osteoporosis following fragility fracture. <i>Osteoporosis International</i> , 2009 , 20, 1911-9	5.3	13
67	Bone turnover markers in the management of postmenopausal osteoporosis. <i>Clinical Biochemistry</i> , 2009 , 42, 929-42	3.5	136
66	Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 153-61	6.3	399
65	Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 495-502	6.3	56
64	The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. <i>Contraception</i> , 2009 , 79, 167-77	2.5	34
63	Low 5-year stability of within-patient ion excretion and urine pH in fasting-morning-urine specimens. <i>Nutrition Research</i> , 2009 , 29, 320-6	4	8
62	Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. <i>Cmaj</i> , 2009 , 181, 265-71	3.5	278
61	Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial 2009 , 24, 153		4
60	Recognizing osteoporosis and its consequences in Quebec (ROCQ): background, rationale, and methods of an anti-fracture patient health-management programme. <i>Contemporary Clinical Trials</i> , 2008 , 29, 194-210	2.3	31
59	Cancer treatment-induced bone loss in breast and prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5465-76	2.2	142
58	The care gap in diagnosis and treatment of women with a fragility fracture. <i>Osteoporosis International</i> , 2008 , 19, 79-86	5.3	124

57	The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. <i>Osteoporosis International</i> , 2008 , 19, 581-7	5.3	110
56	Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2008 , 19, 87-94	5.3	61
55	Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. <i>Journal of Clinical Densitometry</i> , 2007 , 10, 120-3	3.5	76
54	Comparative effects of densitometric and absolute fracture risk classification systems on projected intervention rates in postmenopausal women. <i>Journal of Clinical Densitometry</i> , 2007 , 10, 124-31	3.5	8
53	Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2007 , 18, 1211-8	5.3	58
52	Management of osteoporosis in men: an update and case example. <i>Cmaj</i> , 2007 , 176, 345-8	3.5	22
51	Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 628-32	2.4	36
50	Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 142-8	6.3	109
49	Changes to osteoporosis prevalence according to method of risk assessment. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 228-34	6.3	31
48	Recognizing and reporting vertebral fractures: reducing the risk of future osteoporotic fractures. <i>Canadian Association of Radiologists Journal</i> , 2007 , 58, 27-36	3.9	56
47	The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. <i>Seminars in Arthritis and Rheumatism</i> , 2006 , 36, 10-21	5.3	13
46	Bone strength: the whole is greater than the sum of its parts. <i>Seminars in Arthritis and Rheumatism</i> , 2006 , 36, 22-31	5.3	131
45	Standards for performing DXA in individuals with secondary causes of osteoporosis. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 47-57	3.5	31
44	Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2006 , 21 Suppl 2, P38-44	6.3	106
43	Canadian Consensus Conference on osteoporosis, 2006 update. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2006 , 28, S95-112	1.3	49
42	The natural progression of health-related quality of life: results of a five-year prospective study of SF-36 scores in a normative population. <i>Quality of Life Research</i> , 2006 , 15, 527-36	3.7	55
41	Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. <i>Osteoporosis International</i> , 2006 , 17, 217-24	5.3	12
40	Determinants of health-related quality of life in women with vertebral fractures. <i>Osteoporosis International</i> , 2006 , 17, 355-63	5.3	29

39	Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. <i>New England Journal of Medicine</i> , 2005 , 353, 898-908	59.2	315
38	Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2005 , 27, 759-64	1.3	5
37	Evaluation of easily measured risk factors in the prediction of osteoporotic fractures. <i>BMC Musculoskeletal Disorders</i> , 2005 , 6, 47	2.8	27
36	Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). <i>Osteoporosis International</i> , 2005 , 16, 568-78	5.3	57
35	Recommendations for bone mineral density reporting in Canada. <i>Canadian Association of Radiologists Journal</i> , 2005 , 56, 178-88	3.9	101
34	Stability of normative data for the SF-36: results of a three-year prospective study in middle-aged Canadians. <i>Canadian Journal of Public Health</i> , 2004 , 95, 387-91	3.2	17
33	Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2004 , 20, 757-64	2.5	77
32	Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 111-8	3.5	38
31	Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. <i>Journal of Clinical Densitometry</i> , 2004 , 7, 51-64	3.5	88
30	The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. <i>Developmental Cell</i> , 2004 , 6, 303-9	10.2	266
29	Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. <i>Clinical Therapeutics</i> , 2004 , 26, 15-28	3.5	124
28	Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 784-90	6.3	118
27	The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). <i>Osteoporosis International</i> , 2003 , 14, 895-904	5.3	116
26	What predicts early fracture or bone loss on bisphosphonate therapy?. <i>Journal of Clinical Densitometry</i> , 2003 , 6, 315-22	3.5	15
25	Is there regional variation in the SF-36 scores of Canadian adults?. <i>Canadian Journal of Public Health</i> , 2002 , 93, 233-7	3.2	10
24	The impact of incident vertebral and non-vertebral fractures on health related quality of life in postmenopausal women. <i>BMC Musculoskeletal Disorders</i> , 2002 , 3, 11	2.8	99
23	The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. <i>Calcified Tissue International</i> , 2002 , 71, 103-11	3.9	274
22	Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal women. <i>Osteoporosis International</i> , 2002 , 13, 249-56	5.3	13

21	Intravenous zoledronic acid in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , 2002 , 346, 653-61	59.2	714
20	Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. <i>American Journal of Human Genetics</i> , 2002 , 70, 1582-8	11	448
19	The 2002 Canadian bone densitometry recommendations: take-home messages. <i>Cmaj</i> , 2002 , 167, 1141-5	3.5	13
18	2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. <i>Cmaj</i> , 2002 , 167, S1-34	3.5	316
17	The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. <i>Osteoporosis International</i> , 2001 , 12, 903-8	5.3	205
16	Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 57-63	27.4	134
15	Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. <i>American Journal of Human Genetics</i> , 2001 , 69, 528-43	11	115
14	Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000. <i>Clinical Therapeutics</i> , 2001 , 23, 620-6	3.5	31
13	Positive effect of etidronate therapy is maintained after drug is terminated in patients using corticosteroids. <i>Journal of Clinical Densitometry</i> , 2001 , 4, 363-71	3.5	6
12	Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis. <i>Osteoporosis International</i> , 2000 , 11, 607-14	5.3	11
11	Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. <i>Bone</i> , 2000 , 26, 263-7	4.7	33
10	Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. <i>Cmaj</i> , 2000 , 163, 265-71	3.5	205
9	Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study. <i>Calcified Tissue International</i> , 1999 , 64, 93-9	3.9	37
8	A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. <i>American Journal of Medicine</i> , 1999 , 106, 513-20	2.4	160
7	Research Notes: The Canadian Multicentre Osteoporosis Study (CaMos): Background, Rationale, Methods*. <i>Canadian Journal on Aging</i> , 1999 , 18, 376-387	1.6	169
6	Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 1032-8	6.3	105
5	Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. <i>New England Journal of Medicine</i> , 1998 , 339, 292-9	59.2	1014
4	Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. <i>New England Journal of Medicine</i> , 1997 , 337, 382-7	59.2	608

- 3 Risedronate in Paget's disease: preliminary results of a multicenter study. *Seminars in Arthritis and Rheumatism*, **1994**, 23, 272 5.3 11
- 2 Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. *Journal of Clinical Endocrinology and Metabolism*, **1987**, 64, 954-9 5.6 69
- 1 Eosinophilic synovitis: clinical observations on a newly recognized subset of patients with dermatographism. *Arthritis and Rheumatism*, **1986**, 29, 1147-51 24